Clinical trial · Interventional
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Applicability of Patient Derived Orthotopic Xenograft (PDOX) in Patients With Primary Liver Cancer: A Randomized Controlled Trial
NCT05766605CI-TRIAL-00064642unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma Resectable | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Lobaplatin | Drug | — | UNRESOLVED |
| Lobaplatin, Raltitrexed | Drug | — | UNRESOLVED |
| Oxaliplatin | Drug | Oxaliplatin | ALIAS |
| Oxaliplatin, Leucovorin, fluorouracil | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- the test group
- description
- The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on PDOX results. Precise transarterial chemoembolization at 1-month intervals for 2 months after surgery.
- interventionNames
- Drug: Oxaliplatin
- Drug: Doxorubicin
- Drug: Lobaplatin
- Drug: Cisplatin
- Drug: Oxaliplatin, Leucovorin, fluorouracil
- Drug: Lobaplatin, Raltitrexed
- type
- ACTIVE_COMPARATOR
- label
- the control group
- description
- The control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization with Doxorubicin. Empirical transarterial chemoembolization at 1-month intervals for 2 months after surgery.
- interventionNames
- Drug: Doxorubicin
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Undergone radical surgical resection. 2. Aged 18-75. 3. Patients voluntarily cooperated with the study and signed an informed consent form. 4. Histopathologically diagnosed hepatocellular carcinoma. 5. Patients with R0 resection confirmed by imaging and pathology (no residual lesions and complete tumor resection after radical surgery). 6. Child-Pugh score of 5-7 (A or B), patients with a score of 7 must be free of ascites. 7. ECOG physical fitness status score of 0-1. 8. No serious heart, lung, or renal dysfunction Exclusion Criteria: 1. Unable to provide specimens for PDOX testing. 2. Patients with recurrent liver cancer. 3. Developing two or more types of tumors simultaneously. 4. Patients with existing extrahepatic distant metastases. 5. Treatment with other experimental drugs or other interventions after radical resection. 6. Patients with other malignant tumors that have not been cured within 5 years. 7. Patients with non-radical resections (R1 and R2 resections). 8. Patients with residual or recurrent lesions detected on imaging within 1-2 months after surgery. 9. Died within 1 month after surgery.
References
Publications (0)
Data not yet available
No reference posted for this study.